What is the anti-cancer effect of ribociclib?

Ribociclib (Ribociclib) is a CDK4/6 inhibitor, mainly used to treat hormone receptor-positive (H R+) and human epidermal growth factor receptor2negative (HER2-) advanced breast cancer. In past clinical trials, ribociclib (ribociclib) has demonstrated significant anti-cancer efficacy in the treatment of breast cancer. The following will introduce its anti-cancer efficacy in detail based on clinical experimental data.

1.MONALEESA-2Test:

MONALEESA-2is a pivotal clinical trial ofribociclibfor the treatment ofHR+,HER2- advanced breast cancer. The trial included 668 patients in a randomized, double-blind, placebo-controlled, multicenter clinical trial investigating the efficacy of ribociclib (ribociclib) in combination with dexamethasone in HR+ and HER2- advanced breast cancer.

In trials, ribociclib (ribociclib) showed a significant advantage in progression-free survival (PFS) in patients who were given the drug in combination with dexamethasone. The median progression-free survival time in the treatment group reached 25.3 months, while the median progression-free survival time in the control group was only 16.0 months. This suggests that ribociclib (ribociclib) has significant efficacy in prolonging progression-free survival in patients.

2.MONALEESA-7Test:

The MONALEESA-7 trial is a trial targeting HR+, HER2-Prospective, randomized, double-blind, placebo-controlled clinical trial in advanced breast cancer. The trial was designed to evaluate the efficacy and safety of ribociclib with deoxyestradiol or deoxyestradiol plus dexamethasone in the treatment of untreated HR+, HER2- advanced breast cancer.

As of the time of data analysis, the treatment group of ribociclib with deoxyestradiol or deoxyestradiol plus dexamethasone had significantly better median progression-free survival than the control group. The median progression-free survival in the treatment group was 23.8 months, while the median progression-free survival in the control group was only 13.0 months. This result further confirms the significant efficacy of ribociclib in untreated HR+ and HER2- advanced breast cancer.

3.MONARCH-3Experiment:

The MONARCH-3trial is a pivotal clinical trial ofribociclibin combination with an aromatase inhibitor (AI) for the treatment ofHR+, HER2- advanced breast cancer. The trial enrolled 455 untreated patients and was designed to evaluate the impact of ribociclib (ribociclib) in combination with an AI on progression-free survival (PFS).

In the trial, ribociclib combined with AI showed a significant advantage in median progression-free survival. The median progression-free survival in the treatment group was not estimable, compared with 16.4 months in the control group. This result shows that the combination of ribociclib and AI has significant efficacy in untreated HR+, HER2- and untreated advanced breast cancer.

The above clinical trial data show thatribociclib (ribociclib) is effective in the treatment ofHR+, HER2-It has significant anti-cancer efficacy in advanced breast cancer. It can significantly extend patients' progression-free survival, improve treatment durability, and improve patients' quality of life. However, patients should pay close attention to potential side effects when receiving treatment and perform treatment under the supervision of a doctor to obtain the best treatment results.